Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Opposite Effects of Neuroprotective Cannabinoids, Palmitoylethanolamide, and 2-Arachidonoylglycerol on Function and Morphology of Microglia.

Hohmann U, Pelzer M, Kleine J, Hohmann T, Ghadban C, Dehghani F.

Front Neurosci. 2019 Nov 7;13:1180. doi: 10.3389/fnins.2019.01180. eCollection 2019.

2.

2-Arachidonoylglycerol elicits neuroprotective effects on excitotoxically lesioned dentate gyrus granule cells via abnormal-cannabidiol-sensitive receptors on microglial cells.

Kreutz S, Koch M, Böttger C, Ghadban C, Korf HW, Dehghani F.

Glia. 2009 Feb;57(3):286-94. doi: 10.1002/glia.20756.

PMID:
18837048
3.

Palmitoylethanolamide protects dentate gyrus granule cells via peroxisome proliferator-activated receptor-α.

Koch M, Kreutz S, Böttger C, Benz A, Maronde E, Ghadban C, Korf HW, Dehghani F.

Neurotox Res. 2011 Feb;19(2):330-40. doi: 10.1007/s12640-010-9166-2. Epub 2010 Mar 11.

PMID:
20221904
5.

Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-α.

Scuderi C, Valenza M, Stecca C, Esposito G, Carratù MR, Steardo L.

J Neuroinflammation. 2012 Mar 9;9:49. doi: 10.1186/1742-2094-9-21.

6.

Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility.

Franklin A, Parmentier-Batteur S, Walter L, Greenberg DA, Stella N.

J Neurosci. 2003 Aug 27;23(21):7767-75.

7.

Cannabinoid effects on β amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro.

Janefjord E, Mååg JL, Harvey BS, Smid SD.

Cell Mol Neurobiol. 2014 Jan;34(1):31-42. doi: 10.1007/s10571-013-9984-x. Epub 2013 Sep 13.

PMID:
24030360
8.

Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide.

Facchinetti F, Del Giudice E, Furegato S, Passarotto M, Leon A.

Glia. 2003 Jan 15;41(2):161-8.

PMID:
12509806
9.

Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: possible involvement of different binding sites at the PPARγ receptor.

García C, Gómez-Cañas M, Burgaz S, Palomares B, Gómez-Gálvez Y, Palomo-Garo C, Campo S, Ferrer-Hernández J, Pavicic C, Navarrete C, Luz Bellido M, García-Arencibia M, Ruth Pazos M, Muñoz E, Fernández-Ruiz J.

J Neuroinflammation. 2018 Jan 16;15(1):19. doi: 10.1186/s12974-018-1060-5.

10.

The G protein-coupled receptor 55 ligand l-α-lysophosphatidylinositol exerts microglia-dependent neuroprotection after excitotoxic lesion.

Kallendrusch S, Kremzow S, Nowicki M, Grabiec U, Winkelmann R, Benz A, Kraft R, Bechmann I, Dehghani F, Koch M.

Glia. 2013 Nov;61(11):1822-31. doi: 10.1002/glia.22560. Epub 2013 Sep 3.

PMID:
24038453
11.

Palmitoylethanolamide counteracts substance P-induced mast cell activation in vitro by stimulating diacylglycerol lipase activity.

Petrosino S, Schiano Moriello A, Verde R, Allarà M, Imperatore R, Ligresti A, Mahmoud AM, Peritore AF, Iannotti FA, Di Marzo V.

J Neuroinflammation. 2019 Dec 26;16(1):274. doi: 10.1186/s12974-019-1671-5.

12.

Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice.

Rahimi A, Faizi M, Talebi F, Noorbakhsh F, Kahrizi F, Naderi N.

Neuroscience. 2015 Apr 2;290:279-87. doi: 10.1016/j.neuroscience.2015.01.030. Epub 2015 Jan 28.

PMID:
25637488
13.

The endocannabinoid N-arachidonoyldopamine (NADA) exerts neuroprotective effects after excitotoxic neuronal damage via cannabinoid receptor 1 (CB(1)).

Grabiec U, Koch M, Kallendrusch S, Kraft R, Hill K, Merkwitz C, Ghadban C, Lutz B, Straiker A, Dehghani F.

Neuropharmacology. 2012 Mar;62(4):1797-807. doi: 10.1016/j.neuropharm.2011.11.023. Epub 2011 Dec 13.

PMID:
22186081
14.

Oleoylethanolamide and Palmitoylethanolamide Protect Cultured Cortical Neurons Against Hypoxia.

Portavella M, Rodriguez-Espinosa N, Galeano P, Blanco E, Romero JI, Holubiec MI, Rodriguez de Fonseca F, Fernández-Espejo E.

Cannabis Cannabinoid Res. 2018 Sep 19;3(1):171-178. doi: 10.1089/can.2018.0013. eCollection 2018.

15.

Molecular evidence for the involvement of PPAR-δ and PPAR-γ in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma.

Paterniti I, Impellizzeri D, Crupi R, Morabito R, Campolo M, Esposito E, Cuzzocrea S.

J Neuroinflammation. 2013 Feb 1;10:20. doi: 10.1186/1742-2094-10-20.

16.

Protective Effect of N-Arachidonoyl Glycine-GPR18 Signaling after Excitotoxical Lesion in Murine Organotypic Hippocampal Slice Cultures.

Grabiec U, Hohmann T, Ghadban C, Rothgänger C, Wong D, Antonietti A, Groth T, Mackie K, Dehghani F.

Int J Mol Sci. 2019 Mar 13;20(6). pii: E1266. doi: 10.3390/ijms20061266.

17.

Palmitoylethanolamide and Cannabidiol Prevent Inflammation-induced Hyperpermeability of the Human Gut In Vitro and In Vivo-A Randomized, Placebo-controlled, Double-blind Controlled Trial.

Couch DG, Cook H, Ortori C, Barrett D, Lund JN, O'Sullivan SE.

Inflamm Bowel Dis. 2019 May 4;25(6):1006-1018. doi: 10.1093/ibd/izz017.

PMID:
31054246
18.

Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells.

Kozela E, Pietr M, Juknat A, Rimmerman N, Levy R, Vogel Z.

J Biol Chem. 2010 Jan 15;285(3):1616-26. doi: 10.1074/jbc.M109.069294. Epub 2009 Nov 12.

19.

Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy.

Citraro R, Russo E, Scicchitano F, van Rijn CM, Cosco D, Avagliano C, Russo R, D'Agostino G, Petrosino S, Guida F, Gatta L, van Luijtelaar G, Maione S, Di Marzo V, Calignano A, De Sarro G.

Neuropharmacology. 2013 Jun;69:115-26. doi: 10.1016/j.neuropharm.2012.11.017. Epub 2012 Dec 1.

PMID:
23206503
20.

Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease.

Martín-Moreno AM, Reigada D, Ramírez BG, Mechoulam R, Innamorato N, Cuadrado A, de Ceballos ML.

Mol Pharmacol. 2011 Jun;79(6):964-73. doi: 10.1124/mol.111.071290. Epub 2011 Feb 24.

Supplemental Content

Support Center